NATAP: New HCV Drugs for Treatment-Experienced

[Guest guest]

New HCV Drugs for Treatment-Experienced For those who have previously had peg/RBV treatment but did not achieve an SVR, the usefulness of the new drugs changes a bit. Treatment-experienced patients fall into one of these groups null-responders, partial responders, and relapsers. Vertex reported data from a study at AASLD a few weeks ago for patients who received peg/RBV without their HCV protease telaprevir but after they did not respond to peg/RBV they received telaprevir+peg/RBV. Here is a link to those results. We need to wait for the results from ongoing large phase III studies looking at these types of patients so its too soon to fully understand how they will respond to a regimen of 1 oral drug plus peg/RBV but here are some clues perhaps. The key for many of these patients will be a combination of 2 oral drugs plus peg/RBvJules Levin, NATAPA Study of Telaprevir Combined with Peginterferon Alfa-2a and Ribavirin in Patients with Well-documented Non-response or Relapse After Previous Peginterferon Alfa-2a and Ribavirin Treatment: Interim Analysis - (11/20/08)